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Innate immune responses are essential to host 
defense, yet if unchecked can lead to tissue in-
jury and illness (1). PMN are the primary initial 
immune eff  ectors of acute infl  ammation, and 
these cells use as many as fi  fty toxins for micro-
bial killing in phagocytic vacuoles (2). Incom-
plete closure of phagolysosomes or aberrant 
extracellular release of reactive oxygen species 
(ROS), granule components, lipid mediators, 
hypochlorous acid, and other potentially toxic 
PMN products to surrounding tissues contrib-
ute to injury in several human diseases, includ-
ing the devastating clinical entities of acute 
lung injury (ALI) and acute respiratory distress 
syndrome (ARDS) for which no disease-remit-
ting therapy is currently available (3).
To prevent an overexuberant infl  amma-
tory response and limit damage to the host, 
PMN activation programs need to be tightly
controlled (1). Select membrane-derived lipid 
mediators have recently been described as au-
tacoid regulators of PMN functional responses 
in acute infl  ammation (4). One of these classes of 
antiinfl  ammatory membrane lipids involves iso-
prenoid metabolism. Immune regulatory roles
for isoprenoids are emphasized by the hyper-
IgD and periodic fever syndrome that results 
from low polyisoprenyl phosphate (PIPP) lev-
els secondary to defective mevalonate kinase ac-
tivity (5). Recently, we identifi  ed a novel PIPP
signaling pathway in PMN (6). One of its com-
ponents is presqualene diphosphate (PSDP), 
pres  ent in freshly isolated human PMN in nano-
molar quantities at baseline (i.e., 1.7 nmol/107 
cells) (6). PMN exposure to the chemoattrac-
tant and secretagogue leukotriene B4 (LTB4) 
initiates transient activation of this PIPP sig-
naling pathway with conversion of PSDP to 
its monophosphate form, presqualene mono-
phosphate (PSMP). PSDP carries biological 
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activity as a potent counterregulatory mediator that prevents 
ROS generation (6, 7). In sharp contrast, PSMP is >100-fold 
less active than PSDP for inhibition (6, 7). Thus, incoming 
positive signals for PMN (e.g., LTB4) initiate rapid degrada-
tion and inactivation of an inhibitory lipid signal (i.e., PSDP) 
  coincident with cell responses (e.g., ROS generation). PSDP 
levels quickly return to baseline in a time frame that par-
allels cellular deactivation. Intracellular targets for PSDP to 
control PMN activity remain to be elucidated. Select PSDP 
structural mimetics are also active in vivo, dampening mouse 
responses to zymosan A–induced peritonitis (8).
In addition to PSDP remodeling, LTB4 also initiates 
phosphatidylinositol 3–kinase (PI3K) activation in PMN to 
promote NADPH oxidase assembly and ROS production (9, 
10). Phosphoinositide signaling initiated by PI3Ks is a critical 
early event in PMN responses, such as phagocytosis (11) and 
chemotaxis (12), and contributes to ALI pathogenesis (13). 
Because LTB4 initiates PMN PI3K activation and PIPP re-
modeling, we hypothesized that these signaling events were 
related in the regulation of PMN responses. Here, we report 
that PI3K activity and PSDP remodeling are linked during 
PMN activation and deactivation with direct inhibition of 
PI3K by PSDP to limit PMN responses and lessen the sever-
ity of experimental lung infl  ammation.
RESULTS AND D  I  S  C  U  S  S  I  O  N 
PSDP and PI3K regulate LTB4-triggered O2
− release 
by human PMN
To determine if PSDP and PI3K regulate LTB4-  stimulated 
responses, we exposed freshly isolated human PMN to a 
new structural PSDP mimetic (Fig. 1 A) or a potent and 
specifi  c inhibitor of PI3K activity (LY294002) before LTB4. 
A marked increase in the rate of O2
− generation was observed 
within seconds after LTB4 addition that was transient, slow-
ing considerably by 60 s (Fig. 1 B). The presence of either 
PSDP mimetic (100 nM) or PI3K inhibitor (3 μM) mark-
edly blocked O2
− generation. Exposure to LTB4 (10 min) 
induced 1.6 ± 0.3 nmol O2
−/106 PMN (as compared with 
vehicle 0.5 ± 0.1 nmol O2
−/106 PMN; P < 0.01). Both the 
PSDP mimetic and PI3K inhibitor led to >50% inhibition of 
LTB4-triggered O2
− generation (0.8 ± 0.3 nmol/106 PMN 
and 0.7 ± 0.2 nmol/106 PMN, respectively; P < 0.05) (Fig. 
1 C). The PSDP mimetic concentration in these experiments 
(i.e., 100 nM) was 1,000-fold lower than its critical micellar 
concentration (CMC) ( 100 μM; Fig. S1, at http://www.
jem.org/cgi/content/full/jem.20052143/DC1). To verify 
that the observed inhibition was not secondary to micelle 
formation and sequestration of the lipid agonist LTB4, in 
the next experiments, there was pretreatment with the mi-
metic, a wash, and stimulation with LTB4. Although this ex-
tra step reduced total ROS generation in response to LTB4, 
the PSDP mimetic still led to a >50% decrease (71.2 ±
27.7% inhibition, n = 4). Together, these results indicate 
that human PMN activation by LTB4 is highly dependent 
on PI3K activity and can be inhibited by a new PSDP 
structural mimetic.
Relationship between PI3K activity and PSDP 
during PMN activation
To determine if PSDP remodeling and PI3K activation were 
related, we fi  rst examined their kinetics in human PMN af-
ter exposure to LTB4. Because G protein–coupled recep-
tors can activate class IA and IB PI3Ks (10), we measured 
PIP3 formation in vitro by members of these PI3K classes. 
  After LTB4, p110γ–PI3K activity in PMN rapidly increased 
(within 5 s), reached a maximum rate of activity by 20 s, and 
then declined to basal levels within 30 s (Fig. 2 A, represen-
tative for n = 3). LTB4 also rapidly stimulated p85-based 
PI3K activity in PMN, but at lower levels than p110γ–PI3K. 
By 5 s, signifi   cant decrements were also evident in to-
tal PSDP levels (7.9 ± 1.2%; P < 0.01) (see supplemental 
Figure 1.  Superoxide anion generation by human PMN is regu-
lated by PI3K and PSDP. (A) Structure of PSDP and a new amido PSDP 
structural mimetic (CS ChemDraw software). (B) Freshly isolated human 
PMN were exposed to the PSDP mimetic (100 nM) ( ), a PI3K inhibitor 
(3 μM) ( ), or vehicle ( ) before LTB4 (100 nM) and O2
− generation was 
determined. Results are representative for n = 3. (C) Total O2
− generation 
was also determined for LTB4-activated PMN (10 min) in the presence or 
absence of the test compounds (mean ± SEM; n = 4 from separate PMN 
donors; *, P < 0.01 as compared with vehicle; **, P < 0.05 as compared 
with LTB4).JEM VOL. 203, April 17, 2006  859
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Materials and methods, available at http://www.jem.org/
cgi/content/full/jem.20052143/DC1) that progressed to 
27.1 ± 4.8% reductions (P = 0.001) within 30 s (Fig. 2 B). 
These results indicate that LTB4-triggered activation of PMN 
PI3K and PSDP remodeling was concurrent and temporally 
overlapped with initiation of ROS generation. Although 
both of these signaling events were rapid in onset, the ki-
netics for PI3K activation and deactivation diff  ered from the 
time course for total PSDP remodeling during the initial 30-s 
interval. To determine if PSDP directly interacted with PI3K 
as its activity decreased, PMN were exposed to LTB4 for 
30 s and p110γ−PI3K was immunoprecipitated from cellular 
materials. Lipid extracts were performed and analyzed by gas 
chromatography/mass spectrometry (GC/MS) (6). Selective 
ion monitoring at m/z 137 (2 isoprenoid units) revealed a 
unique peak at 18.1 min in LTB4-exposed PMN extracts. MS 
spectral diagnostic ions (Fig. 2 C), namely m/z 567 [M+
 − 
(H2O)], 488 [M+
 − (H2PO4)], 410 [M+
 − (HP2O7)], 341 
[M+
 − (HP2O7)  − 69], 205 {M+ − [HP2O7]  − 69 − 
[CH2C(CH3)CHCH2 × 2]}, 137 [C10H17], 97 [H2P2O7], 
81 [CH2C(CH3)CH(CH2)2  − H +] and 69 [base peak; 
(CH3)2CCHCH2], were consistent with authentic PSDP in 
the PI3K immunoprecipitated material.
Direct inhibition of p110𝗄–PI3K by PSDP
Because PI3K activity and PSDP remodeling were both early 
signaling events in PMN with interaction between PSDP and 
p110γ–PI3K, next we questioned if PSDP could directly reg-
ulate PI3K activity. Recombinant human (rh) p110γ–PI3K 
activity was determined by PIP3 formation in vitro in the 
presence of PSDP, PSMP, or the PI3K inhibitor LY294002. 
PIP3 formation was signifi  cantly decreased by PSDP (800 
pmol) with 94.7 ± 5.3% inhibition (P < 0.001) and a PI3K 
inhibitor (500 pmol) with 46.7 ± 6.7% inhibition (P = 0.01) 
(Fig. 3 A). PSDP inhibited p110γ–PI3K in a concentration-
dependent fashion (Fig. 3 B). In sharp contrast, PSMP (8–800 
pmol) did not signifi  cantly impact p110γ–PI3K activity. The 
IC50 for PSDP (38 pmol) had a stoichiometry with PI3K of 
 9:1. These results indicate that PSDP is a potent direct in-
hibitor of p110γ–PI3K with a structure–activity relationship 
that suggests an important role for the diphosphate structure 
in PSDP’s action on p110γ–PI3K activity. The LTB4-me-
diated PMN remodeling of PSDP corresponds to an  50 
pmol change in PSDP/106 PMN, a decrease that is within 
the concentration range for regulation of p110γ–PI3K ac-
tivity (Fig. 3 B). After cell activation, the percent change in 
total PSDP (i.e., 28%) is similar to the change in phosphati-
dylinositol (17%) that occurs in activated PMN membranes 
(14). Collectively, our new fi  ndings indicate that receptor-
  mediated agonists for PMN remodel PSDP in time-frames 
and amounts consistent with functional impact on PI3K ac-
tivity and cellular responses.
PSDP remodeling in vivo during tissue injury 
and infl  ammation
Because PI3K activity occupies a central role in regulating 
PMN activation during lung injury and infl  ammation (13), 
next we determined PSDP remodeling in vivo in mouse 
lungs during an experimental model of mild ALI secondary 
Figure 2.  Relationship between PI3K activity and PSDP in acti-
vated human PMN. 5 × 106 PMN were exposed to 100 nM LTB4 and 
both PI3K activity and PSDP levels were measured at timed intervals. 
(A) Representative time course (n = 3) in PMN lysates for p110γ- ( ) 
and p85-based ( ) PI3K activity. (B) PSDP levels in activated PMN were 
measured in parallel with PI3K. Values reported are the percentage of 
change in PSDP (mean ± SEM; n = 4, *, P < 0.001). (C) PMN were ex-
posed to LTB4 (100 nM, 37°C) for 30 s and p110γ–PI3K was isolated by 
immunoprecipitation with a specifi  c antibody. Lipids were extracted from 
the immunoprecipitates and taken to GC/MS. Ions (m/z) present in mate-
rials bound to p110γ–PI3K were diagnostic for PSDP as noted in the inset.860  PIPP SIGNALING REGULATES PI3K ACTIVITY | Bonnans et al.
to aspiration of gastric acid (15), which is a common clinical 
event (3). To simulate acid aspiration, hydrochloric acid (HCl) 
(0.1 N, pH = 1.5) was selectively instilled into the animals’ 
left lungs (15). Lung PMN infi  ltration was maximal 12 h after 
HCl injury (14.2 ± 1.8 vs. 5.5 ± 0.8 × 104 PMN/mg lung; 
P < 0.01) (Fig. 4 A). Expression of class IA and IB PI3Ks 
in mouse lungs were both increased at 2 and 12 h after HCl 
(Fig. 4 B). Lungs were removed and lipid extracts were pre-
pared for PSDP determination. Of interest, despite increased 
PMN numbers, PSDP levels were signifi  cantly lower in the 
left lungs of HCl-injured mice (4.6 ± 0.3 μg PSDP vs. 9.0 ± 
1.6 μg PSDP in control lungs; P < 0.02). These results indi-
cate that experimental lung injury led to decrements in PSDP 
concomitant with increased PMN, suggesting an inverse rela-
tionship in vivo between lung PSDP and infl  ammation.
PSDP mimetic blocks PMN infi  ltration and PI3K activity
To determine if PSDP can block pulmonary infl  ammation 
and PI3K in vivo, we administered a PSDP structural mimetic 
(0.8 μg/mouse, i.v.) or vehicle 15 min before HCl instillation 
into the left main-stem bronchus. PSDP markedly reduced 
lung PMN 12 h after injury (Fig. 5 A). Tissue morphometry 
on LY-6G–stained histological sections (for identifi  cation of 
mouse PMN) revealed signifi  cant inhibition with the PSDP 
mimetic (46.8 ± 7.1% LY-6G staining [HCl] vs. 18.8 ± 5.8% 
LY-6G staining [HCl plus PSDP mimetic]; P < 0.05) (Fig. 
5 B). In view of the prominent class IA PI3K lung expression 
that increased markedly after ALI (Fig. 4 B), we next deter-
mined class IA PI3K activity after acid injury in the presence 
or absence of the PSDP mimetic. HCl injury induced signifi  -
cant increases in lung PI3K activity in p85 immunoprecipi-
tates (0.59 ± 0.17 PIP3/mg lung with HCl vs. 0.05 ± 0.02 
pmol PIP3/mg lung with PBS; P < 0.05). Administration 
of the PSDP mimetic blocked the HCl-induced increase in 
class IA PI3K activity to near basal levels (0.05 ± 0.01 pmol 
PIP3/mg lung; P < 0.05) (Fig. 5 C). Thus, PSDP can regulate 
PMN activation, tissue accumulation, and total PI3K activity 
in vivo during experimental acid-initiated ALI.
During acute infl   ammation, PI3Ks orchestrate several 
cellular responses for host defense, including PMN ROS 
generation (12). Befi  tting its central role in cell activation, 
several mechanisms are in place to restrain PI3K activity 
(16–18).   Previous reports have suggested a link between de-
creased PIPP formation and increased PI3K (19, 20). Results 
presented here are the fi  rst to demonstrate direct inhibition 
of PI3K by a PIPP and inverse relationships between PI3K 
Figure 3.  PSDP directly blocked PI3K activity. (A) rhp110γ–PI3K 
activity was determined in the presence or absence of PSDP (800 pmol), 
PSMP (800 pmol), or a PI3K inhibitor (500 pmol). (B) Concentration re-
sponse for the impact of PSDP ( ) or PSMP ( ) on rhp110γ–PI3K activ-
ity (mean ± SEM; n = 3; *, P < 0.05 as compared with vehicle).
Figure 4.  ALI induced PMN infi  ltration, PI3K, and PSDP remodeling. 
(A) 12 h after HCl-initiated ALI, PMN accumulation was determined 
by MPO activity in lung homogenates (n = 5; *, P = 0.002). (B) Semi-
quantitative RT-PCR for p85 and p110γ–PI3K mRNA expression in the 
injured lungs 2 and 12 h after HCl instillation (n = 3; *, P < 0.05). 
(C) PSDP levels were measured in lung lipid extracts with or without 
HCl-initiated injury (12 h; mean ± SEM; n = 3–4; *, P < 0.05).JEM VOL. 203, April 17, 2006  861
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  activity and PSDP levels both in vitro and in vivo. In addi-
tion, PSDP bound to p110γ–PI3K in activated PMN and 
potently inhibited rhp110γ-PI3K in vitro and a PSDP struc-
tural mimetic blocked PI3K activity in vivo. Together, these 
new fi  ndings support a signaling relationship between PI3K 
and PIPPs in the regulation of leukocyte functions during 
infl  ammation.
Pivotal regulatory properties have been ascribed to 
  isoprenoids. For example, polyisoprenyl glycolipids form 
  antigen complexes with CD1 to activate T cells (21), and 
cholesterol is critical to PMN cell membrane organization 
and polarization in response to chemotactic stimuli (22). Al-
though PIPPs are appreciated as cholesterol biosynthetic 
  intermediates, PSDP is also present in cells, such as human 
PMN, that cannot use it for cholesterol biosynthesis because 
they lack squalene cyclase and other mixed function oxidase 
activities (23). There are now several lines of evidence to 
support a role for PSDP as a counterregulatory signal in PMN 
functional responses. PSDP is a constituent of PMN cell 
membranes (20), and receptor activation leads to rapid and 
transient PIPP remodeling. PSDP is a potent and direct in-
hibitor of phospholipase D (PLD) with at least two interac-
tion domains on human PLD1b for PSDP (8). PSDP also 
interacts with Src-homology 2 (SH2) domains on the adap-
tor protein Grb2 (24) and blocks NADPH oxidase assembly 
in a cell-free assay (6). PSDP displays anti-PMN properties in 
vitro and in vivo, and PSDP structural mimetics are able to 
dampen leukocyte-driven infl  ammation (8). Here, we have 
identifi  ed PI3K as a new target for regulation by PSDP. The 
physical interaction between PI3K and PSDP and absence of 
regulatory proteins in our in vitro system indicate that PSDP 
can directly inhibit p110γ–PI3K. Similar to PLD (8), the di-
phosphate moiety of PSDP was also important for PI3K in-
hibition, and the stoichiometry suggests multiple potential 
sites for PSDP and PI3K interaction. Both class IA and IB 
PI3Ks translocate to membranes via interactions with Ras 
that is activated, in part, via isoprenylation (25). These shared 
isoprenoid moieties with PSDP may provide additional sites 
of interaction outside the PI3K catalytic center. Of interest, 
PSDP and PI3K are present in resting PMN in complemen-
tary intracellular locations (cell membranes and cytosol, re-
spectively), and both translocate to intracellular organelles 
upon cell activation (20, 26).
Activated PMN contribute to the development and se-
verity of tissue injury during infl  ammatory illnesses such as 
ALI. No specifi  c therapy is currently available to modulate 
the infl  ammatory response to airway injury from acid and 
protect the lung in ALI. PI3K is an important enzyme in the 
proinfl  ammatory PMN signaling program of ALI, as p110γ–
PI3K defi  ciency dampens the severity of endotoxin-induced 
ALI (13). In addition to PMN, PI3Ks are also activated dur-
ing ALI in lung-resident cells (27) and both endothelial cell 
and PMN PI3Ks contribute to PMN accumulation in the 
lung (28). Select lipid mediators, namely lipoxin A4 (LXA4), 
inhibit PI3K in structural cells (29). LXA4 signaling also pro-
motes resolution of experimental ALI (15) and inhibits PMN 
activation by LTB4 in a postreceptor manner, in part by 
blocking PSDP remodeling (7). Here, PSDP levels were 
Figure 5.  PSDP reduced acid-initiated ALI. (A) PSDP structural mi-
metic (0.8 μg/mouse) or vehicle was administered (i.v.) 15 min before HCl 
injury. 12 h after HCl instillation, histological specimens were prepared 
and mouse PMN were identifi  ed by LY-6G immunostaining (arrows). Bar, 
100 μm. (B) Tissue morphometry was performed to determine 
the percentage of LY-6G staining cells in mouse lungs (n = 4 measure-
ments in each group; *, P < 0.05 as compared with HCl-injured left lung). 
(C) Class IA (p85-based) PI3K activity was determined in lung lysates after 
ALI. Data are mean ± SEM. n = 3; *, P < 0.05 as compared with control; 
**, P < 0.05 as compared with HCl-injured lung.862  PIPP SIGNALING REGULATES PI3K ACTIVITY | Bonnans et al.
  decreased in acid-injured lungs and a novel PSDP mimetic 
blocked PI3K, PMN ROS generation, and PMN accumula-
tion in the lung. Because the PSDP mimetic was adminis-
tered intravenously, regulation of cells other than PMN may 
have also contributed to the marked inhibition of leukocyte 
traffi   cking after acid injury.
In conclusion, the ability of PSDP and a new PSDP mi-
metic to directly inhibit PMN early intracellular activating 
signals, such as PI3K, and to lessen the infl  ammation associ-
ated with experimental ALI provides insight into new mech-
anisms for in vivo protection from excess PMN-driven 
infl  ammation and tissue injury. Together, our fi  ndings sug-
gest that PIPP signaling pathways, and specifi  cally PSDP, can 
serve as natural templates for the design of new therapeutic 
strategies in infl  ammatory diseases.
MATERIALS AND METHODS
Materials. PSDP and PSMP were isolated from human PMN or prepared 
by total organic synthesis (8). The bisphosphonate PSDP structural mimetic, 
tetraethyl presqualene carboxamido-methylene-diphosphonate was prepared 
from presqualene carboxylic acid. All synthetic compounds were character-
ized by NMR spectroscopy.
Human PMN incubations. Peripheral blood was obtained by venipunc-
ture from healthy volunteers who denied taking any medications for at least 
2 wk and had given written informed consent to a protocol approved by 
Brigham and Women’s Hospital’s Human Research Committee. PMN 
were isolated from whole blood as described previously (6). Freshly isolated 
PMN (1–5 × 106 PMN/ml HBSS plus 1.6 mM CaCl2) were incubated 
(5 min, 37°C) in the presence of 3 μM LY294002, 100 nM PSDP mimetic, 
or vehicle (0.1% ethanol), then exposed to LTB4 (100 nM) in the presence 
of 7 mg/ml cytochrome c. This concentration of LTB4 was chosen because 
it initiates PMN NADPH oxidase assembly (7) and is similar to amounts 
measured in vivo at sites of acute infl  ammation (30). In some incubations, 
PMN in HBSS without calcium were exposed to PSDP mimetic or vehicle, 
pelleted by centrifugation (700 g, 3 min), and resuspended in HBSS plus 
1.6 mM CaCl2 without PSDP before the addition of agonist. Superoxide 
anion generation was determined (37°C) as superoxide dismutase-inhibitable 
cytochrome c reduction by monitoring (550 nm) at 5-s intervals in a continu-
ously fl  owing water-bath–jacketed cassette or after timed incubations. For 
PSDP identifi  cation, PMN (50–100 × 106 cells/ml) were activated (LTB4 
100 nM, 30 s) before disruption by N2 cavitation (350 psi, 20 min, 4°C). 
Remaining intact cells and nuclei were pelleted (500 g, 10 min, 4°C) and 
  supernatants were used for immunoprecipitation with anti-p110γ−PI3K 
(4°C). After overnight incubation, washed protein A agarose (60 μl) was 
added and incubated for 2 h at 4°C. After several washes, the immunopre-
cipitates were saponifi  ed, lipids were extracted, and materials were analyzed 
by GC/MS (Hewlett-Packard) (6). Injections in 2–5 μl CHCl3 were made 
onto a fused-silica capillary DB-17 column (30 mm, 0.25 mm i.d.) obtained 
from J&W. Scientifi  c with helium as carrier gas and a column temperature 
program (150–260°C at 15°C per min−1).
Measurement of class IA and IB PI3K activity. After immunopre-
cipitation with either an anti-p85 or anti-p110γ–PI3K selective antibody, 
PI3K activity from PMN and lung homogenates was determined by PIP3 
formation in vitro using a competitive ELISA (Echelon Biosciences Inc.). 
For recombinant purifi  ed PI3K enzyme, activity was determined by a lu-
minescent kinase assay (Kinase-Glo; Promega) that quantitated decrements 
in ATP by kinase utilization. rh p110γ–PI3K (4 pmol/reaction) was ex-
posed (15 min, 37°C) to PSDP or PSMP (0.4–800 pmol) followed by 25 μg 
l-α-phosphatidylinositol and 1 μM ATP and allowed to react for 90 min 
at room temperature. Incubations were stopped with 50 μl of Kinase-
Glo reagent and incubated an additional 10 min at room temperature. 
  Luminescence was measured with a FLx800 microplate luminometer (Bio-
Tek Instruments, Inc.).
Experimental model of ALI. All animal protocols were approved by the 
Harvard Medical Area Animal Institutional Review Board. Acid (0.1 N HCl, 
pH = 1.5, 50 μl) was instilled intratracheally into the left lung of anesthetized 
mice (FVB, male, 10–12 wk; Charles River Laboratories) (15). A PSDP mi-
metic (0.8 μg in 100 μl 0.9% saline) or vehicle (1% ethanol) was administered 
by tail vein 15 min before HCl instillation. After 12 h, lungs were removed, 
prepared for MPO (15) or PI3K assay, or were fi  xed in IHC zinc buff  er and 
paraffi   n embedded for immunostaining with LY-6G (1:50 dilution). Area and 
number of positively staining cells was measured with National Institutes of 
Health Image software and percentage of positive cells/area calculated.
Statistical analysis. Results are expressed as the mean ± SEM. Statistical 
signifi  cance of diff  erences was assessed by Student’s t test and one-way analy-
sis of variance. P < 0.05 was set as the level of signifi  cance.
Online supplemental material. Fig. S1 shows the CMC determination 
for the PSDP mimetic and related compounds. Further information on ma-
terials and experimental protocols are supplied as the supplemental Materials 
and methods. Online supplemental material is available at http://www.jem.
org/cgi/content/full/jem.20052143/DC1.
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